RHHBY Roche Holding AG
Company Analysis
Latest News
🟢 Roche is trading 3.04% up today after Deutsche Bank upgrade citing positive giredestrant feedback
Roche is trading at $61.43, up 3.04%, after Deutsche Bank’s upgrade to Buy, citing positive physician feedback on its cancer drug giredestrant. - On October...
Roche Beats Q3 Sales Forecasts, Confirms Full-Year Guidance
Roche reported third-quarter group sales of 16.13 billion Swiss francs ($19.57 billion). That exceeded the average analyst forecast of 15.78 billion francs....
Roche reports 55% lower relapse rate with fenebrutinib
Roche reported new Phase III data showing that its investigational multiple sclerosis (MS) drug fenebrutinib reduced markers of chronic brain...
🟢 Roche is trading 3.45% up today as healthcare led U.S. sector gains
Roche is trading 3.45% higher at $59.11 on October 21, 2026, following a strong healthcare-sector advance. - Healthcare led U.S. sector gains on October 20;...
🟢 Roche is trading 3.2% up on October 20, 2026, amid a broader healthcare-sector rally
Roche is trading at $58.95, up 3.17%, in a move consistent with a healthcare-sector rally; healthcare was the S&P 500’s best-performing sector as investors...
Roche's Itovebi Denied NHS Use Over Trial Doubts and High Cost
The UK's National Institute for Health and Care Excellence (NICE) has rejected routine NHS use of Roche's breast cancer drug Itovebi (inavolisib). The decision...
Roche licenses Rona obesity drug in deal worth up to $1.16B
Roche Holding AG has licensed an experimental obesity drug from Chinese biotechnology firm Rona Therapeutics, securing exclusive worldwide rights. The deal...
Roche advances vamikibart as FDA accepts filing, one-year data show sustained gains
Roche reported one-year results from its Phase III MEERKAT and SANDCAT studies of vamikibart, an investigational eye injection for uveitic macular edema (UME)....
Roche Wins FDA Approval for Tecentriq in Stage III dMMR Colon Cancer
Roche said Genentech has received FDA approval for Tecentriq (atezolizumab) with chemotherapy as adjuvant treatment for stage III deficient mismatch repair...
Roche Reports Up to 9.2% Weight Loss, but Blood-Sugar Effect Lags
Roche and partner Zealand Pharma announced topline results from a Phase 2 trial of petrelintide in patients with Type 2 diabetes. The trial ran for 28...
🟢 Roche is trading 3.01% up
Roche is trading 3.01% higher at $54.11 on October 7, 2026, with no clear company-specific catalyst identified. - No clear company-specific announcement...
Roche Targets AI Input in 80% of Research Portfolio Decisions by 2026
At Pharma Day 2026, Roche Holding AG outlined plans to integrate artificial intelligence into drug development, including building autonomous, AI-driven...
Roche Lunsumio Combination Hits Phase III Goal, Improving Lymphoma Outcomes
Roche’s Phase III CELESTIMO study for Lunsumio (mosunetuzumab) met its primary endpoint. The trial evaluated Lunsumio combined with lenalidomide for patients...
🟢 Roche is trading 3.89% up today after partner MediLink's positive Phase III TAISHAN-302 results
Roche is trading 3.89% up now at $54.80 after partner MediLink reported positive Phase III TAISHAN-302 results on September 13, 2026. - Tam-Peli reduced...
Roche Surges on Blockbuster Lung Cancer Data, but Can a China-Only Trial Justify a Global Bet Worth Hundreds of Millions?
Shares of Roche shifted sharply higher on September 14, rising +4.1% to $55.39 even as broader U.S. indices traded lower — a clear sign the market is pricing...
🟢 Roche is trading 4.05% up today after positive interim Phase III Tam-Peli results
Roche is trading 4.05% up now at $54.86 after collaborator MediLink reported positive interim Phase III TAISHAN-302 results on September 13, 2026. - Tam-Peli...
🟢 Roche is trading 5% up today after positive Phase III Tam-Peli results
Roche is trading sharply higher at $55.39 (+4.98%) on September 14, 2026, after collaborator MediLink reported positive interim Phase III TAISHAN-302 results...
Roche Lung Cancer Drug Tam-Peli Slashes Death Risk by 54%
Roche Holding AG and collaborator MediLink reported positive interim results from the Phase III TAISHAN-302 trial. The study evaluated Tam-Peli (tambotatug...
Roche Secures FDA Priority Review for Enspryng, Targeting Untreated Rare Disease
The FDA granted Priority Review for Roche’s supplemental Biologics License Application for Enspryng. The treatment targets myelin oligodendrocyte glycoprotein...
🟢 Roche is trading 3% up today on healthcare-sector strength
Roche is trading at $55.45, up +3.03%, alongside a healthcare sector gaining 1.37% in regular trading. - The S&P 500, Nasdaq, and Dow are each gaining more...